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ABSTRACT
Objectives: Intrahepatic cholestasis of pregnancy (ICP) is the most common liver disorder during pregnancy. Cholestasis 
is associated with increased risk of fetal complications: prematurity, perinatal hypoxia and meconium stained amniotic 
fluid, and sudden intrauterine fetal death. The exact mechanisms associated with cholestasis fetal sequelae are not fully 
understood. The aim of the study was the histopathological evaluation of placentas from patients with cholestasis and 
healthy pregnant women to establish whether cholestasis is accompanied by changes in placental microstructure. 
Material and methods: The effect of cholestasis on placental microstructure was investigated using placental tissue from 
patients with cholestatsis treated with ursodeoxycholic acid (UDCA) and from uncomplicated pregnancies. Five placental 
histopathological features were analyzed: number of syncytial knots, number of capillaries per villous, structure of stroma, 
presence of Hofbauer cells, and villitis of unknown etiology. 
Results: There were no statistically significant differences in any of the studied parameters between cholestasis-affected 
and healthy control groups.
Conclusions: There are no diffrences in placental microstructure in cholestasis patients treated with UDCA and in patients 
with uncomplicated pregnancy.
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INTRODUCTION
Intrahepatic cholestasis of pregnancy is the most com-
mon liver disorder during pregnancy, occurring in 1% of 
pregnancies. Very frequently ICP develops during the late 
second and third trimesters. Pregnant women with cholesta-
sis present characteristic symptoms: pruritus, especially dur-
ing the night, associated with abnormal liver function. These 
signs usually resolve after delivery. Among others, the most 
important biochemical feature of ICP is elevated serum bile 
acid levels (> 10 mmol/L) [1]. Cholestasis is associated with 
increased risk of fetal complications: prematurity, perinatal 
hypoxia and meconium stained amniotic fluid, and sudden 
intrauterine fetal death [2]. The increased risk of detrimental 
perinatal results correlates with high bile acid concentration 
(> 40 mmol/L) [3]. The exact mechanisms associated with 
cholestasis fetal sequelaes are not fully understood. In the 
normal course of pregnancy, the total concentration of bile 
acids in fetal serum is only sligthly higher than in maternal 
serum. Because the fetal hepatobiliary and renal systems are 
not fully developed and cannot eliminate bile acids, the lat-
ter must be transferred across the placenta to be eliminated 
by the maternal liver. In patients with cholestasis, as a result 
of high levels of bile acids in the serum, the transplacental 
bile acid gradient is reversed, causing impairment placental 
transport [1, 4].
Bile acids induce vasoconstriction of the chorionic ves-
sels in the placenta that causes impaired fetal-maternal 
transport across the placenta, damage of the placental 
structure and reduced transport of nutrients and oxygen 
to the fetus. 
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Little is known about the effect of intrahepatic cholesta-
sis of pregnancy on the placental structure. Most reports 
involving sudden intrauterine fetal death are not connected 
with prominent morphological changes in the placenta or 
the features of its chronic insufficiently [5, 6].
The aim of the study was to evaluate the histopathologi-
cal changes of placentas from patients with cholestasis and 
healthy pregnant women to establish whether cholestasis 
affects placental microstructure.
MATERIAL AND METHODS
Twenty patients with intrahepatic cholestasis and 40 wom-
en as controls with physiological pregnancy who delivered in 
2018 in the Gynecologic and Obstetrical University Hospital, 
Poznan, Poland were qualified to this prospective case-control 
study. Recognision of cholestasis was determined after ex-
cluding other liver diseases (viral hepatitis, acute fatty liver of 
pregnancy, pre-eclampsia, primary biliary cirrhosis and HELLP 
syndrome), on the basis of unexplained itching associated 
with increased bile acid (> 10 mmol/L) and liver dysfunctions. 
We also excluded patients with complications of pregnancy 
other than ICP. We included patients with physiological preg-
nancy in the control group. Patients in the control group did 
not have cholestasis in their previous pregnancy or pruritus 
in the previous or current pregnancy. Inclusion criteria for 
pregnant women with cholestasis and controls demanded 
that all patients have single, live-born newborn.
All participants gave written informed consent. The ob-
tained data included concentration of transaminases and 
bile acid at the time of diagnosis and delivery, gestational 
week at diagnosis and delivery, the highest concentration 
of bile acid and transaminases, neonatal birth weight, um-
bilical pH value, Apgar score, placental weight, and pla-
cental/neonatal birth weight ratio (Tab. 1). All women with 
ICP were treated with ursodeoxycholic acid (UDCA). All the 
participants were nonsmokers.
The study was approved by the Ethical Committee of 
Poznan University of Medical Sciences.
Collection of samples and slide preparation
After delivery placentas were weighed and fixed in 4% 
buffered formalin for 10 days. After fixation, the samples 
were dehydrated using in sequence: 70–100% series of ethyl 
alcohol dilutions, xylene, and embedded in 58°C paraffin. 
Samples were cut at 5 mm using a microtome (Leica SM 
2010R) and mounted on slides. The slides were incubated 
for 2 h at 58°C to remove excess paraffin and ensure laminar 
adhesion. Deparaffinization was performed in three changes 
of xylene for 10 min each. Next, the slides were rehydrated 
through a 100–70% series of ethyl alcohol dilutions and 
washed in distilled water. Finally, deparaffinized samples 
were stained with hematoxylin and eosin (HE) and examined 
with a light microscope with camera attachment (Axioskop 
40 ZEISS) with 100x and 400x magnification.
Histology
Histological analysis of the preparations (n = 20 ICP pa-
tients, n = 40 control patients) was performed by pathologist 
unaware of gestational age and disease status. 
Evaluation of syncytial knots
The definition of syncytial knots was described by 
Geenes et al. [7] as the presence of at least 10 aggregated 
syncytiotrophoblast nuclei that were not in direct contact 
with communicating villi surfaces. They illustrate areas of 
intensified apoptosis. In pregnancies with a pathological 
course complicated by intrauterine growth restriction and 
pre-eclampsia the amount of syncytial knots enhances.This 
phenomenon is a result of increased placental apoptosis. 
Exposure placental explant patches to influence of hyper-
oxia, hypoxia or reactive oxygen species in vitro causes 
creation of syncytial knots [7].
Table 1. Characteristics of maternal and delivery outcomes: values expressed as median (range) or mean (± SD)
ICP (n = 20) Control (n = 40) P value
Maternal characteristics
Age [years] 30 (± 5) 30 (± 5) 0.869
Gravity 1 (1–6) (1–4) 0.402
Parity 0–5 0–3 0.415
Fetal characteristics
Gestation age at delivery [weeks] 37 (± 2) 38 (± 2) 0.698
Birth weight [g] 2892 (± 683) 3623 (± 2763) 0.043
Apgar score 5 minutes 10 (5–10) 10 (8–10) 0.058
Umbilical artery pH 7.3 (7.2–7.5) 7.3 (7.1–7.5) 0.516
Placental weight [g] 529 (± 42) 544 (± 68) 0.164
Placenta/naonatal birth weight ratios 0.16 (0.02–0.038) 0.18 (0.13–0.62) 0.001
454
Ginekologia Polska 2019, vol. 90, no. 8
www. journals.viamedica.pl/ginekologia_polska
In each placental sample, in three fields of view, the 
number of syncytial knots was counted manually. A count 
of syncytial knot density per mm2 of villous tissue was al-
lowed by the determination the surface area of villous tissue 
in the frames.
Evaluation of Hofbauer cells (HBCs)
Hofbauer cells are fetal origin [8]. They are placental vil-
lous macrophages, which emerge in placental tissue from 
18 days after conception and persist to the end of pregnancy. 
By the fourth to fifth month of pregnancy, their identification 
becomes difficult as villous stroma becomes compressed [9]. 
Functions of tissue macrophages are phagocytosis of cellular 
debris and antigen presentation in response to infectious 
agents and inflammation [10]. Due to villitis of unknown 
etiology (VUE) and varial infection HBCs proliferation or 
hyperplasia is observed [11, 12]. In placentas from compli-
cated pregnancies (gestational diabetes mellitus, intrauter-
ine growth restriction, pre-eclampsia), the number of HBCs 
seems to increase while in placentas from uncomplicated 
pregnancies, HBCs either disappear or become less in num-
ber after the fourth month of pregnancy [13].
HBCs were identified as round or ovoid cells with eccen-
tric nuclei and granular cytoplasm. The HBCs were counted 
in two high-power fields per slide at 400× magnification 
from three different fields in each section. The mean value 
per villous was calculated (Tab. 2). 
Villitis
Villitis arises due to hematogenous infection of the pla-
centa by TORCH infection. In contrast, majority of cases are 
immune mediated and are not an effect of infection [14]. 
There are two types of villitis: acute and chronic.In the first 
type of villitis, which is often a result of infection, polymor-
phonuclear leukocytes infiltrate the villi with or without 
associated necrosis. Whereas in the second type of villitis 
the tissue is infiltrated by macrophages and lymphocytes 
usually with concomitant fibrosis and cellular proliferation 
of the villi [15, 16].
Statistical Analysis
For statistical analysis, SigmaStat version 3.5 software 
(Systat Software, Inc., Point Richmond, CA, USA) was used. 
The analysis of the results was based on the Student’s t-test 
for variables with parametric distributions. For variables with 
non-parametric distributions, the Mann–Whitney rank sum 
test was used. The Fisher exact test was used for assessment 
of the villitis distribution. P < 0.05 was considered statisti-
cally significant.
RESULTS
Biochemical characteristics of the ICP patient’s popula-
tion is shown in the Table 3. There were no differences in 
neonatal,maternal and obstetrical outcomes. Neverthe-
less, there was a statistically significant difference in birth 
weights (2892 ± 683 g vs 3623 ± 2763 g, p = 0.043) and pla-
centa/neonatal birth weight ratios (0.16 vs 0.18, p = 0.001) 
in neonates born to women with and without cholestasis, 
respectively (Tab. 1). 
The histological slides of 20 patients with ICP and 40 
healthy controls were examined. Placentas from both 
groups were found to be appropriate for their gestational 
age. Five placental histopathological features were ana-
lyzed: number of syncytial knots, number of capillaries per 
villous, structure of stroma, presence of HBCs, and VUE. The 
placentas from both groups exhibit normal microstructure: 
compact stroma and appropriate number of capillaries per 
villous (< 10). 
There were no statistically significant differences in any 
of the remaining three parameters between the cholestasis 
and healthy control groups (Tab. 3). Representative images 
are shown in Figure 1.
Table 2. Placental histology of the study population
ICP (n = 20) Control (n = 40) P value
Hofbauer cells/villous [median (range)] 2 (0–5) 1 (0–3) 0.397
Syncytial knots [median (range)] 21 (12–34) 15 (9–29) 0.143
Structure of stroma compact compact –
Villitis of unknown etiology 1 (5%) 3 (7.5%) 0.999
Number of capillaries per villous < 10 < 10 –
Table 3. Biochemical characteristic of ICP patient population, median (range)
Sample Week of delivery [week] Bile acid(highest value) [mmol/L]
Alat 
[U/L]
Aspat
[U/L]
Bile acid at delivery
[mmol/L]
N = 40 37 (± 2) 37.5(11–171.3)
188.1
(13.5–1228.9)
101.2
(16.7–695.2)
22.4
(10.8–102)
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DISCUSSION
In this paper, we analyzed the histopathological images 
of placentas of patients with pregnancy complicated with 
cholestasis, and non-complicated, phisiological pregnancy. 
All pregnant women with cholestasis were treated with 
UDCA which is considered the first-line treatment for ICP, 
because it normalizes the transplacental bile acid gradient, 
significantly reducing fetal and maternal bile acid levels [17]. 
Five placental histopathological features were analyzed: 
number of syncytial knots, number of capillaries per villous, 
structure of stroma, presence of HBCs and VUE. In our study, 
we did not find any differences in the microstructure of the 
placenta of patients with cholestasis relative to patients with 
normal pregnancy.
Our results are in accordance with Patel et al. [18] who 
compared the placentas of 24 pregnant women with ICP and 
30 healthy women. They found no differences in maternal, 
neonatal, and obstetrical outcomes. They found a significant 
difference between the groups only in the gestation age 
at delivery. Patients with cholestasis delivered two weeks 
earlier than the controls. The authors analyzed 17 placental 
histopathological parameters and didn’t find statistically 
significant differences in any of these features between 
patients with cholestasis and healthy pregnant women. 
Comparison of the placentas from women, treated and not 
treated with UDCA, demonstrated a statistically significant 
reduction in VUE (9% vs 53%, p = 0.03), which implies that 
UDCA has an anti-inflammatory impact on the placenta. 
However, the exact mechanism by which UDCA decreases 
placental inflammation is not known. 
Guven et al. [19] investigated the alterations in the 
architecture of the umbilical cord and the placenta in se-
lected pregnancy complications. They stated a significant 
enhancement in the amount of syncytial knots in placentas 
from women with pre-eclampsia, oligohydramnions, poly-
hydramnions, and repeated cesarean sections, but not in ICP 
Figure 1. Representative images villi of trophoblast in a 20× (A, B) and 40× (A1, B1) lens magnification microscope stained by H + E obtained 
from women with normal pregnancy (A, A1) and with pregnancy complicated by cholestasis (B, B1) treated with ursodeoxycholic acid. The green 
arrows indicate the syncytial knots (A, B) and Hofbauer cells (A1, B1).
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and control groups. Furthermore, they found a significant 
reduction in the diameter and volume of the arterial lumen 
of an umbilical artery in the ICP group compared to the 
control group. The arterial tunica intima and tunica media 
were thicker in ICP than in the control group. 
The available data of the histopathological analysis of 
placenta in patients with cholestasis and its comparison 
with that of the group of healthy pregnant women indicates 
morphological differences. These changes include higher 
amount of syncytial knots and enhancement surface of 
terminal villi, and were observed in pregnant women with 
cholestasis untreated with UDCA. 
In the article of Geenes et al. [20] slides prepared from 
28 ICP patients and 12 healthy controls were subjected to 
histological examination. In the placentas achieved from 
pregnant women with cholestasis a couple of morphological 
abnormalities were found to be more frequent as compared 
to the placentas from physiological pregnancies. These con-
tained chorionic villi that had dense fibrotic stroma and were 
small for the gestational age, focally-thickened amniotic 
basement membranes, increased in number of syncytial 
knots and stricture of intervillous space. The number of 
syncytial knots was significantly higher in placentas from 
untreated women with ICP compared to those from un-
complicated pregnancies (p = 0.02). However, there was 
no significant difference in the amount of syncytial knots 
in the placentas achieved from women with cholestasis 
treated with UDCA compared to healthy pregnant women.
Wikström Shemer et al. [21] in a prospective case-control 
study using the computerized stereology method, examined 
placentas from 10 untreated and 10 UDCA-treated patients 
with cholestasis, and eight healthy pregnant women for mor-
phological differences. They analyzed five histopathological 
features of placentas (volume fraction of collagen, surface 
area of terminal villi and capillaries, chorangiosis,anumber 
of syncytial knots and volume of placenta).
The results of their research demonstrated that cholesta-
sis influences the microarchitecture of placenta by enhance-
ment the number of syncytial knots and terminal villous and 
capillary surface area. The UDCA treatment had protective 
effect on placental micro architecture. The analyses of pla-
centas of UDCA-treated cholestasis, compared to untreated 
ICP, showed statistically significant differences in amount 
of syncytial knots, capillary surface area and terminal vil-
lous. The statistical differences were not detected in any 
analyzed parameters in placentas between UDCA-treated 
cholestasis patients and healthy pregnant women.
Increased capillary growth in terminal villi and syncy-
tial knots were both described as a sign of hypoxia which 
is commonly evident in placentas coexisting with diseas-
es with reduced blood perfusion (diabetes mellitus and 
pre-eclampsia).
Conclusions from the two abovementioned cited stud-
ies indicate that ICP is associated with a couple of anomalies 
of the placenta microstructure, including an enhancement 
in the amount of syncytial knots. However, in placentas of 
women treated with UDCA, the number of syncytial knots 
was comparable to those in placentas from uncomplicated 
pregnancies [20, 21].
 The studies of Geenes et al. [20], Wikström Shemer et 
al. [21], and Patel et al. [18] were published in 2011, 2012, 
and 2014 respectively and, probably for that reason, some 
patients did not receive treatment with UDCA which is cur-
rently the first-line treatment for cholestasis.
The final answer to the question, whether treatment 
with UDCA in women with cholestasis improves obstetric 
outcomes, will be obtained after the completion of the tri-
ple-masked, placebo-controlled, randomised trial — PITCHES 
(Phase III trial in IntrahepaTic CHolestasis of pregnancy to 
Evaluate urSodeoxycholic acid in improving perinatal out-
comes) which is currently randomized [22].
Our study has a number of limitations. Our work was 
carried out on a relatively small group of patients, but the 
real cholestasis, confirmed with biochemical data is rather 
rare in our population. To reduce statistical error, the his-
tological examination of placentas should be carried out 
on a larger and an independent cohort. All patients with 
cholestasis included in this study, as well as all patients 
with cholestasis who delivered in 2018 in Gynecologic and 
Obstetrical University Hospital in Poznan, were treated with 
UDCA before delivery. UDCA treatment of pregnant women 
with cholestasis is standard in our hospital; therefore it was 
not possible to compare placental microstructure between 
patients with pregnancy complicated by cholestasis treated 
and not treated with UDCA.
CONCLUSIONS
Based on obtained results, we can conclude that the 
histopathological structure of the placenta of patients with 
cholestasis treated with UDCA does not differ from women 
with normal pregnancy.
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